These results suggest that CDK7 inhibitors elicit a response in cancer cells similar to compounds that target regulators of cell cycle progression (PLK3, HSP90, HDACs, EGFR), whereas CDK9 inhibitors produce responses similar to drugs targeting mitosis (i.e., microtubule stability and dynamics). This evidence concerns the gene PLK3 and cancer.